Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer

Abstract

ABSTRACT. We conducted a cohort study to investigate the role of 3 single-nucleotide polymorphisms of the excision repair crosscomplementation group 1 (ERCC1) gene on the response to chemotherapy and clinical outcomes of non-small cell lung cancer (NSCLC). A total of 163 patients with newly diagnosed and histopathologically confirmed primary NSCLC were examined in our study and were followed up until December 2012. ERCC1 rs11615, rs3212986, and rs2298881 were selected and genotyped. Of the 163 patients, 86 patients showed a complete response and partial response to chemotherapy (52.76%), while 91 patients (55.83%) died from NSCLC during the follow-up period with a median survival time of 19.3 months (range, 2-60 months). Multivariate regression analysis showed that individuals carrying the rs11615 TT genotype and T allele had a significantly lower response rate to chemotherapy using the rs11615 CC genotype as the reference. For rs3212986, carriers of the rs3212986 AA genotype and A allele had a significantly lower response rate to chemotherapy when compared with the CC genotype. In the Cox proportional hazards model, patients carrying the rs11615 TT genotype and T allele and the rs3212986 AA genotype and A allele were significantly associated with increased risk of death from NSCLC. We found that polymorphisms in ERCC1 rs11615 and rs3212986 were associated with poor response to chemotherapy and shorter survival time of advanced NSCLC.

Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma

“…Cheng et al (2012) found that the C allele of ERCC1 rs11615 polymorphism was associated with longer response to cisplatin-based chemotherapy in treatment of last-stage NSCLC than T allele. Gao et al (2014) found that the ERCC1 polymorphisms rs11615 and rs3212986 were negatively associated with response to chemotherapy and survival time of patients with advanced NSCLC. Li et al (2014b) found that ERCC1 rs11615 was positive associated with risk of death in patients with gastric cancer.…”

“…Multiple previous studies have reported that ERCC1 and ERCC2 were associated with the response to cisplatin-based chemotherapy and clinical outcome in several cancers (Kamikozuru et al, 2008;Park et al, 2011;Cheng et al, 2012;Ren et al, 2012;Chen et al, 2013;Rumiato et al, 2013;Gao et al, 2014;Li et al, 2014b). Park et al (2011) reported that the ERCC1 rs3212986 polymorphism was correlated with treatment outcome of metastatic gastric cancer treated with cisplatin-based chemotherapy.…”

Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma

“…Many epidemiologic studies have reported that ERCC1 polymorphisms may influence the outcome of cisplatin treatment in gastric cancer, non-small cell lung cancer (NSCLC), ovarian cancer, and esophageal squamous cell carcinoma (Qi et al, 2013;Chen et al, 2014;Gao et al, 2014;Liu et al, 2014). Liu et al (2014) conducted a cohort study to investigate the role of ERCC1 gene polymorphism in response to chemotherapy and clinical outcome in gastric cancer, and did not find the ERCC1 rs3212986 polymorphism to be associated with OS in gastric cancer.…”

“…Liu et al (2014) conducted a cohort study to investigate the role of ERCC1 gene polymorphism in response to chemotherapy and clinical outcome in gastric cancer, and did not find the ERCC1 rs3212986 polymorphism to be associated with OS in gastric cancer. Gao et al (2014) also conducted a cohort study to investigate the role of three SNPs of ERCC1 in the clinical outcome of NSCLC, and found that the TT genotype of ERCC1 rs11615 and the AA genotype of rs3212986 polymorphisms were associated with increased risk of death from NSCLC. Chen et al (2014) showed that the ERCC1 rs3212986 polymorphism showed a significant association with survival in epithelial ovarian cancer patients.…”

A functional single‐nucleotide polymorphism in the ERCC 1 gene alters the efficacy of narrowband ultraviolet B therapy in patients with active vitiligo in a Chinese population

“…Previous studies have demonstrated that single‐nucleotide polymorphisms (SNPs) in those NER genes could affect DNA repair capacity, adjust DNA adduct accumulation, serve as a sensitive biomarker for cancer chemotherapy response and be associated with increased risk of death from cancer . Specifically, the XPA A23G AA genotype showed lower DNA repair capacity, while the GG genotype has been reported to increase the risk of basal and squamous cell carcinoma and lung cancer .…”